SCHEMBL5583002

SCHEMBL5583002

c1ccc(COc2cncc(-c3cccnc3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.56
CYP11B1 P15538 5/20 0.54
CYP11B2 P19099 5/20 0.54
CYP19A1 P11511 3/20 0.54
GRM5 P41594 1/20 0.53
MAPT P10636 1/20 0.52
SMPD1 P17405 1/20 0.51
IKBKB O14920 1/20 0.50
CHRNB2 P17787 3/20 0.49
CHRNB4 P30926 2/20 0.49
CHRNA3 P32297 2/20 0.49
CHRNB1 P11230 1/20 0.49
CHRNB3 Q05901 1/20 0.49
CYP3A4 P08684 1/20 0.49
CHRNA4 P43681 2/20 0.48
PRMT5 O14744 1/20 0.48
CHRNA7 P36544 1/20 0.48
SIRT2 Q8IXJ6 1/20 0.47
SIRT1 Q96EB6 1/20 0.47
SIRT3 Q9NTG7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1957530 0.84 MAPK1 (0.61) MAPK1CYP11B1CYP11B2CYP19A1MAPT
SCHEMBL4506543 0.84 CYP11B2 (0.68) MAPK1CYP11B1CYP11B2CYP19A1MAPT
SCHEMBL30150593 0.82 RAB9A (0.62) MAPK1MAPTCHRNB2CHRNA4MEN1
SCHEMBL1323646 0.82 RAB9A (0.62) MAPK1MAPTCHRNB2CHRNA4MEN1
SCHEMBL8512404 0.82 MAOB (0.56) MAPK1MAPTCYP3A4MEN1KMT2A
SCHEMBL6833618 0.81 AKT1 (0.68) MAPK1CYP11B1CYP11B2IKBKBCYP3A4
SCHEMBL12129613 0.81 GRM5 (0.62) MAPK1CYP11B1CYP11B2CYP19A1GRM5
Bromide SCHEMBL27462942 0.80 RAB9A (0.60) MAPK1MAPTCHRNB2CHRNA4MEN1
SCHEMBL27650249 0.80 INPPL1 (0.53) CYP11B1CYP11B2CYP19A1GRM5CHRNB2
SCHEMBL30338964 0.80 CYP11B1 (0.70) MAPK1CYP11B1CYP11B2CYP19A1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070027321-A1 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-02-01 US disclosed
EP-1664018-A1 BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-06-07 EP disclosed
WO-2005021529-A1 BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027321-A1 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRM1 MAPK1 2462/4885CYP11B1 1221/4885CYP11B2 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.